A biosimilar is a biologic product that is highly similar to another approved biologic product, known as “reference product”, and has no clinically meaningful differences in terms of effectiveness, safety or exposure from the reference product.1
We bring years of pharmaceutical development experience to offer high-quality biosimilars to patients
In line with our corporate philosophy of “caring for life”, we have entered into the biosimilars area, as a part of our passion and commitment to unlocking access to lifesaving medicines for more patients.
Well positioned to achieve this goal, Fresenius Kabi is equipped with extensive experience in the manufacture and supply of injectables and complex formulations, as well as global expertise in the development of biologics.
In the areas of oncology and immunology, Fresenius Kabi applies the same high-quality standards in developing and producing biosimilars as is required for the reference product.
1. European Medicines Agency (EMA). Biosimilars in the EU: Information guide for healthcare professionals. 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf (accessed in December 2020).